The evaluation of drug interactions in prescriptions for heart disease patients at the XYZ pharmacy in 2024
Abstract
Background: Cardiovascular disease is a major cause of morbidity and mortality, with treatment commonly involving polypharmacy, which increases the risk of drug interactions. Methods: This study aimed to evaluate potential pharmacokinetic drug interactions in prescriptions of heart disease patients at XYZ Pharmacy in 2024. This study used a descriptive observational design with a retrospective approach through prescription review. A total of 45 prescriptions that met the inclusion criteria were selected using total sampling. Data were analyzed descriptively using frequency and percentage. Results: The results showed that most prescriptions contained 3–4 drugs (62.2%), indicating polypharmacy. A total of 92 potential drug interaction cases were identified, consisting of 79.30% pharmacodynamic interactions and 20.70% pharmacokinetic interactions. Pharmacokinetic interactions occurred during the absorption, distribution, metabolism, and excretion phases, with examples including digoxin–spironolactone, clopidogrel–lansoprazole, and metformin–furosemide. The most common interaction combinations occurred between cardiovascular drugs (54.35%). Conclusion: In conclusion, there are potential pharmacokinetic drug interactions in prescriptions of heart disease patients at XYZ Pharmacy in 2024. These findings highlight the importance of drug interaction screening in pharmaceutical services to improve the safety and effectiveness of therapy.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.